Cardio Diagnostics Holdings partners with Navierre for cardiac testing

AI-enabled cardiovascular firm Cardio Diagnostics Holdings introduced it’s partnering with care-navigation platform Navierre to make assessing threat and diagnosing coronary heart illnesses extra accessible. 

Cardio Diagnostics Holdings’ AI options, Epi+GenCHD and PrecisionCHD, use blood samples to offer sufferers with customized info concerning their threat for coronary coronary heart illness primarily based on epigenetic and genetic science. 

PrecisionCHD, launched in 2023, detects coronary coronary heart illness markers utilizing AI with out using specialised healthcare infrastructure. 

The checks could be performed at dwelling, in a clinic or by way of cellular phlebotomy. 

The companions plan to deliver cardiac care to underserved communities that lack entry to conventional cardiac care, together with rural areas. 

Navierre clinicians can order a take a look at or sufferers can create a profile and request the take a look at from dwelling. The corporate pairs sufferers with telehealth clinicians and permits sufferers to trace their well being information, insurance coverage and drugs historical past in a single app. 

“Cardio Diagnostics’ groundbreaking testing options are an thrilling addition to our curated listing of services we provide to our customers. By combining our progressive platform with their AI-driven precision diagnostics, we empower sufferers and clinicians with the instruments they should determine cardiovascular threat early when it may be most successfully addressed. Collectively, we’re making important strides within the struggle in opposition to the world’s main reason for demise,” Mustafa Dinani, CEO and cofounder of Navierre, mentioned in a press release. 

THE LARGER TREND

In December, Cardio Diagnostics introduced it regained Nasdaq minimal bid necessities after posting a closing bid worth of $1 for ten consecutive days. The corporate acquired discover their inventory itemizing worth was not in compliance with Nasdaq in September. Earlier than regaining compliance, the inventory worth reached a low of $.20. The corporate’s inventory is at present buying and selling at $1.16 as of the time of publishing.  

Cardio launched a brand new platform in January known as HeartRisk, which employers who use Cardio’s scientific testing companies can make the most of to deal with heart problems within the office. 

Navierre was based in 2022, in response to an SEC submitting, and in March, added two board members, Jeff Stelnik of Blue Cross Blue Defend of Arizona and Gaurav Singhvi of AFC Wimbledon, in March. The corporate mentioned the brand new additions will deliver healthcare accessibility and management expertise to Navierre’s board.